Navigation Links
FDA Approves First Insomnia Drug for Middle-of-the-Night Waking Followed By Difficulty Returning to Sleep
Date:11/23/2011

SILVER SPRING, Md., Nov. 23, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Intermezzo (zolpidem tartrate sublingual tablets) for use as needed to treat insomnia characterized by middle-of-the-night waking followed by difficulty returning to sleep.  

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

This is the first time the FDA has approved a drug for this condition. Intermezzo should only be used when a person has at least four hours of bedtime remaining. It should not be taken if alcohol has been consumed or with any other sleep aid.

Insomnia is a common condition in which a person has trouble falling or staying asleep. It can range from mild to severe, depending on how often it occurs and for how long. Insomnia can cause excessive daytime sleepiness and lack of energy. It also can make a person feel anxious, depressed, or irritable. People with insomnia may have trouble focusing on tasks, paying attention, learning, and remembering.

Zolpidem tartrate was first approved in the United States in 1992 as the drug Ambien.  Intermezzo is a lower dose formulation of zolpidem. The recommended and maximum dose of Intermezzo is 1.75 milligrams for women and 3.5 mg for men, taken once per night. The recommended dose for women is lower because women clear zolpidem from the body at a lower rate than men.

"For people whose insomnia causes them to wake in middle of the night with difficulty returning to sleep, this new medication offers a safer choice than taking a higher dose of zolpidem upon waking," said Robert Temple, M.D., deputy center director for clinical science in the FDA's Center for Drug Evaluation and Research. "With this lower dose there is less risk of a person having too much drug in the body upon waking, which can cause dangerous drowsiness and impair driving."

Intermezzo was studied in two
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015 RadiologyAuction will have their ... video and product demonstrations at the end of the ... such as Kodak and Fuji Cr,s, Agfa and Sony, ... the first event. Various imaging equipment will be available ... After years of buying and selling imaging ...
(Date:5/4/2015)... , May 4, 2015  Oncobiologics, Inc., a ... antibody (mAb) biosimilars, has completed the construction of ... headquarters in Cranbury, New Jersey ... facility is designed to utilize multiple technologies ... commercial scale.  Through the use of the latest ...
(Date:5/4/2015)... CARLSBAD, Calif. , May 4, 2015  Isis ... an exclusive license agreement with Bayer HealthCare (Bayer) to ... of thrombosis. Under the terms of the agreement, Isis ... near-term payments, including an immediate $100 million up-front payment ... program following a Phase 2 study in patients with ...
Breaking Medicine Technology:RadiologyAuction Announces Event Starting On May 5th 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5
... , NEW YORK, Nov. 19 As ... is here. Here,s more on preparing yourself. , Listen to ... http://inr.mediaseed.tv/oneClip_C/?feed=ksLp_frMYEE7RzdnRfCsbxc9R2VXAOIF , Medialink is a division ... text, graphics and photos at http://www.thenewsmarket.com . ...
... , , NEWPORT NEWS, Va., Nov. 19 ... recognized and endorsed by two highly esteemed organizations for ... Imaging (SBI) and the American College of Surgeons. Both ... breakthrough imaging technology for the early detection of breast ...
Cached Medicine Technology:Esteemed Endorsements Recognize Promising Future of Breast-Specific Gamma Imaging (BSGI) 2Esteemed Endorsements Recognize Promising Future of Breast-Specific Gamma Imaging (BSGI) 3
(Date:5/4/2015)... 04, 2015 Dr. Richard Champagne, DMD, ... chosen to receive the America’s Best Dentist Award, given ... selection as a top dentist is a reflection of ... education and his compassion for his patients. , Each ... exemplify excellence in their field. These nominees are dentists ...
(Date:5/4/2015)... Sylvia Hawthorn-Deppen shared her experiences living with ... others in similar situations that they were not alone, in ... Discovery of New Energy” (published by Balboa Press). This year ... renewed press campaign. , “I have spent nearly 60 years ... says. “As an adolescent I got into trouble with an ...
(Date:5/4/2015)... Vista, California (PRWEB) May 04, 2015 ... introduced a brand new lubricant -- Astroglide TTC™ ... impede sperm motility and alter pH levels, Astroglide TTC™ ... conception. , According to the Centers for Disease ... have trouble getting pregnant or sustaining a pregnancy, ...
(Date:5/4/2015)... 04, 2015 “ Food Cost Calculator ” ... which takes a look at the latest and coolest applications ... the host of AppWatch and technology expert, conducted the app ... owners to manage and efficiently calculate food costs. , The ... In fact, the industry has an estimated 1.8 trillion dollar ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 ... just released the first-ever congenital heart disease ... Catheterization Laboratory (PCCL) accreditation. Driven by the ... are a comprehensive review of interventional procedures ... heart disease. , “The ACE CHD Standards ...
Breaking Medicine News(10 mins):Health News:New Jersey Dentist Dr. Richard Champagne Nominated for America’s Best Dentist Award 2Health News:Author launches new press campaign for 2012 book ‘Wheel’ 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 3Health News:An Application to Manage a Successful Restaurant Was Featured on NewsWatch Television 2Health News:Accreditation for Cardiovascular Excellence (ACE) Publishes New Standards for Pediatric and Adult Congenital Cardiac Catheterization Laboratories 2
... CLEVELAND, Feb. 4 Franklin & Seidelmann,( ... market penetration into the hospital sector with the,addition of ... , , -- Barnes-Kasson Hospital, Susquehanna, ... Owenton, KY, -- Syringa General Hospital, ...
... Kensey Nash Corporation (Nasdaq: KNSY ), a leading ... a wide range of medical procedures, today announced the resignation ... Ramius LLC, from its Board of Directors.Mr. Smith became a ... member of the Corporate Governance and Nominating Committee as well ...
... counterfeit and adulterated medicines posing an increasing risk to ... Pharmacopeial (USP) Convention today announces new standards for two ... episodes of adulteration resulting in patient deaths. , ... heparin and the sweetener glycerin, comes on the heels ...
... Impacts One in Four Americans Show Features Real People with ... Bob Schieffer and Denver Broncos, Quarterback Jay CutlerWESTPORT, Conn., Feb. ... today the new 2009 television schedule for dLifeTV ... people living with diabetes, airing every Sunday on CNBC at ...
... U.S. Preventive Medicine(R), the leader in disease prevention ... Christopher Fey, Chairman and CEO, and Fred Goldstein, President ... Services Conference, to be held February 9-11 in New ... U.S. Preventive Medicine will participate in this exclusive conference ...
... and special product offerings available in store during ... CVS/pharmacy, America,s largest retail pharmacy, will mark American ... about maintaining heart health and preventing heart disease. ... month on many heart health-related products.Heart disease is ...
Cached Medicine News:Health News:Franklin & Seidelmann Expands into Critical Access Hospital Market Provides 24 x 7 Teleradiology Service for Three New Clients 2Health News:Franklin & Seidelmann Expands into Critical Access Hospital Market Provides 24 x 7 Teleradiology Service for Three New Clients 3Health News:Kensey Nash Announces Director Resignation 2Health News:USP announces new standards to protect patients from counterfeit and adulterated medicines 2Health News:dLifeTV Announces New Season Programming and Celebrity Guests; Only Nationally-Broadcast Program About Diabetes Celebrates 5th Year and 200th Show 2Health News:dLifeTV Announces New Season Programming and Celebrity Guests; Only Nationally-Broadcast Program About Diabetes Celebrates 5th Year and 200th Show 3Health News:U.S. Preventive Medicine(R) Executives to Present at 2009 UBS Global Healthcare Services Conference 2Health News:CVS/pharmacy Taking Health to Heart in February 2Health News:CVS/pharmacy Taking Health to Heart in February 3
The New Vantage Plus. The PLUS gives you: ,P Premium intelligent optics ,L Lighter weight and brighter images ,U Unique wireless patented technology ,S Smaller and more compact size ...
STAT-CRIT is a rapid, one-step system for measuring hematocrit....
... Simple, compact, and easy to use, ... surgery technology to every OR. The business ... provide hospitals and surgeons with the most ... their facilities. ,The z-boxTM is designed to ...
...
Medicine Products: